Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (7) , 501-512
- https://doi.org/10.2165/00019053-200321070-00005
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- ObesityNew England Journal of Medicine, 2002
- Standards of Medical Care for Patients With Diabetes MellitusDiabetes Care, 2002
- Reducing the Cost of Frequent Hospital Admissions for Congestive Heart FailureMedical Care, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S.Diabetes Care, 1998
- Economic Consequences of Diabetes Mellitus in the U.S. in 1997Diabetes Care, 1998
- The Cost of ObesityPharmacoEconomics, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDMDiabetes Care, 1991